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Multiple sclerosis (MS) is an autoimmune
disease caused by the infiltration of autore-
active lymphocytes into the central nervous
system (CNS). The influence of B cells
has been underestimated for a long time.
Recently, it has become more apparent that
B cells can fundamentally contribute to the
pathogenesis of MS in terms of antigen
presentation, co-stimulation, cytokine pro-
duction, ectopic lymphoneogenesis, and
antibody secretion (1–3). Along these lines,
B cell depletion in MS patients with a
relapsing-remitting disease course was able
to reduce inflammatory brain lesions and
clinical relapses (4) and B cell activation
influences T cell polarization in the ani-
mal model of MS (5). Great effort has been
made to utilize B cells for dividing patients
into subgroups and to predict treatment
responses in individual patients to spe-
cific drugs (6). Especially the detection of
autoantibodies against CNS antigens is a
crucial research subject due to its capabil-
ity to be used as disease-specific biomarkers
for the diagnosis and prognosis of MS.
To this end, in a clinical study pub-
lished in 2012 in the New England Jour-
nal of Medicine, Srivastava and colleagues
screened serum samples aiming to iden-
tify CNS-specific antibodies in MS (7).
The authors identified the glial potassium
channel KIR4.1 as one of the serum anti-
body targets in MS patients. Subsequently,
an enzyme-linked immunosorbent assay
(ELISA) large-scale screening with 397 MS
patients, 329 persons with other neurolog-
ical diseases, and 59 healthy donors was
performed. Antibodies against KIR4.1 were
observed in 46.9% of patients with MS, but
were essentially absent in people with other
neurological diseases and healthy donors.
Based on these data, Srivastava et al. con-
cluded that KIR4.1 is a CNS-specific target
of the autoantibody response in a subgroup
of patients with MS.
We would like to carefully raise the pos-
sibility that the serum IgG reactivity against
KIR4.1 might present an epiphenomenon
and there could be an additional target for
autoreactive B cells beyond the CNS. It has
to be considered that KIR4.1 is not only
expressed in the CNS, but also on parietal
cells of the gastric mucosal epithelium (8).
The KIR4.1 channel expression is essential
for the parietal cell control of acid secre-
tion (9, 10). It is well known that there is
a connection between the gastrointestinal
immune response and CNS autoimmunity
(11, 12). There are several possible mecha-
nisms including molecular mimicry, deter-
minant spreading, or bystander activation
explaining the link between gastrointesti-
nal immune response and MS (13). As
recently published by Banati et al. (11),
antibodies against parietal cells are also
present in the sera of patients with MS.
The presence of anti-parietal cell antibod-
ies was most frequently associated with gas-
trointestinal complaints of the MS patients
(11). Thus, it is possible that an impaired
gastric mucosa, which can appear in cases
of a frequent corticosteroid therapy, could
extensively expose the parietal cell KIR4.1
to B cells. Corticosteroids augment gas-
troduodenal permeability and high doses
are associated with macroscopic mucosal
lesions (14).
Therefore, we consider it as necessary
to include the history of gastrointestinal
complaints in the anamnesis of the study
subjects before defining KIR4.1 as a CNS
target of serum antibodies. In the setting of
patients with an initial demyelinating event
who have not received corticosteroids, one
could readily exclude an impact of the MS
medication on the gut. Finding anti-KIR4.1
antibodies in such patients in combination
with gut impairments could raise the pos-
sibility that the gut itself is also a target of
the autoimmune process.
While further investigations are awaited
to clearly analyze the impact of immune
responses against antigens of gastric pari-
etal cells on the finding of KIR4.1-reactive
antibodies in patients with MS, the diag-
nostic potential of serum KIR4.1 antibod-
ies may be highly clinically relevant. There-
fore, the sensitivity and specificity of the
initial findings of serum KIR4.1 antibod-
ies in a subgroup of MS patients should
be confirmed in studies from independent
researchers.
Furthermore, the pathogenicity of
KIR4.1 antibodies needs to be clarified.
Only 2 of 19 serum IgG positive MS
patients also had detectable levels of
KIR4.1 antibodies in the cerebrospinal
fluid (CSF) (7). By analogy, aquaporin-
4 antibodies were not readily detected in
the CSF in neuromyelitis optica patients
(15). Immunhistochemical investigations
by Lennon et al. (16) showed that serum
aquaporin-4 antibodies in patients with
neuromyelitis optica bind to CNS tissue as
well as to parietal cells of the gastric mucosa
(16). However, it is beyond doubt that
aquaporin-4 antibodies are highly patho-
genic in neuromyelitis optica since they
were studied extensively. Kinoshita and col-
leagues have demonstrated the pathogenic
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role of aquaporin-4 antibodies in vivo (17).
They obtained serum IgG from patients
with neuromyelitis optica and detected
astrocytic damage in rats after passive
transfer of aquaporin-4 containing IgG.
In vivo experiments of this kind could
delineate whether KIR4.1 antibodies are
only a disease marker or if they play
a central pathogenic role. To this end,
KIR4.1 antibody containing serum could
be injected into mice and subsequent his-
tological and immunohistochemical inves-
tigations could show potential resulting
pathological effects in CNS and gut. Fur-
thermore, astrocytes should be incubated
with KIR4.1 antibody containing serum
and cell viability assays may demonstrate
whether KIR4.1-reactive IgG induces astro-
cytic cytotoxicity.
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